Delirium as a Presenting Symptom of COVID–19

Brad Tyson, PsyD,* Ayman Shahein, MD,† Laszlo Erdodi, PhD,‡ Leigh Tyson, BSN, RN,§ Robert Tyson, MD,∥ Reza Ghomi, MD,* and Pinky Agarwal, MD*

Background: Delirium is a common neurologic manifestation of coronavirus disease 2019 (COVID–19) in older adults who present to the emergency department (ED).

Objective: To investigate clinical characteristics associated with delirium as a presenting symptom of COVID–19 in older adults and develop a logistic regression to predict the likelihood of delirium.

Method: We compared clinical characteristics in an age- and gender-matched sample of 68 delirious individuals with 68 nondelirious individuals (Mean age = 78) who presented to the ED with COVID–19.

Results: The delirious group was more likely to have neurologic, psychiatric, and cardiovascular comorbidities; a prior history of delirium; and deliriogenic medications in their medication list. They were less likely to present with respiratory symptoms and more likely to present with sepsis, hypoxia, higher heart rate, and higher sodium. The delirious group had higher mortality (51%) than the nondelirious group (32%). Delirium developed within an average of 2 days of initial COVID–19 symptom onset, with symptom onset to ED within an average of 4 days and symptom onset to death within an average of 11 days. Logistic regression based on five delirium predictors correctly predicted 80% of those with delirium (75% sensitivity at 86% specificity).

Conclusion: Our results are largely consistent with prior studies and suggest that delirium is a common, early occurring, and lethal manifestation of COVID–19 in older adults presenting to the ED, in most cases causing acute on chronic neurocognitive dysfunction strongly influenced by inflammatory and hypoxic–ischemic mechanisms.

Key Words: COVID–19, delirium, neurology, psychiatry, neuropsychology

COVID–19 = coronavirus disease 2019. ED = emergency department. SARS–CoV-2 = severe acute respiratory syndrome coronavirus 2.

The authors declare no conflicts of interest.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

METHOD

Participants

We collected data through a clinical chart review of 516 consecutive individuals with SARS–CoV-2 infection seen in the ED between February 20, 2020, and July 8, 2020, at EvergreenHealth Medical Center—the first hospital with reported SARS–CoV-2 cases in the United States. EvergreenHealth Medical Center is a public...
hospital serving nearly 850,000 people in the King and Snohomish counties of Washington State. It has 318 hospital beds, including 20 beds in the intensive care unit and 15 beds in the hospice care center. The hospital experienced 47,643 ED visits and 13,819 acute care admissions in 2020.

The comparison group consisted of the first 68 individuals matching the age and gender of the delirious group who were seen in the ED during the same data collection period. Both groups had SARS-CoV-2 infection confirmed by polymerase chain reaction testing of a nasopharyngeal sample.

The study protocol was approved by the institutional review board and ethics committee of the EvergreenHealth Medical Center of Kirkland, Washington, and was performed according to the ethical guidelines of the Declaration of Helsinki and its later amendments.

**Materials**

We collected data regarding relevant demographic characteristics, medical history, medications, presenting signs and symptoms of COVID–19, vital signs and available laboratory findings in the ED, hospitalization characteristics, and individual outcomes. Presenting signs and symptoms were reported by the individuals themselves, family members, care partners, nursing staff, emergency responders, and physicians. Determination of deliriogenic medications was based on the Beers criteria for potentially inappropriate use in older adults (2019 American Geriatrics Society Beers Criteria Update Expert Panel, 2019) and included documented daily use of anticholinergics, antiepileptic drugs, antihistamines, antipsychotics, benzodiazepines, and/or opioids. We gathered additional information regarding baseline mental status, hospitalization characteristics, and individual outcomes from outpatient office visit notes, nursing and progress notes, consultation reports, discharge summaries, and death reports.

A neurologist (P.A.) and neuropsychologist (B.T.) independently reviewed all patient medical records and cross-referenced presenting symptoms. We established the diagnosis of delirium using the Chart-based Delirium Identification Instrument (Inouye et al, 2005), which is a well-validated method for identifying the presence of delirium based on evidence in the medical record. Delirium was defined as acute disturbance of attention and awareness representing a decline from baseline mental status. We considered key words such as altered mental status, confusion, delirium, disorientation, encephalopathy, decreased level of consciousness, and impaired consciousness. We excluded individuals if (a) their mental status changes did not clearly represent a decline from a previously higher baseline, (b) they were comatose at hospital admission, (c) their medical records lacked sufficient data to substantiate the diagnosis, and/or (d) there was a lack of consensus between P.A. and B.T.

**Statistical Analysis**

Descriptive statistics (M, SD, percentage, LR, OR, and 95% CI) were computed for relevant variables. The statistical significance of between-group differences was determined using independent t tests (two-tailed) and $\chi^2$. Effect size estimates were expressed in Cohen’s $d$. A logistic regression classifier was used to predict delirium as a presenting symptom of COVID–19 with the addition of lasso regularization to avoid overfitting, as our data comprised a high-dimensional set of clinical metrics. We used MATLAB’s Statistics and Machine Learning Toolbox function, lasso.glm.

The clinical predictors used in our model, motivated by our univariate group comparison, included the use of deliriogenic medication, history of dementia, history of stroke, prior delirium, and assisted versus independent living residence. Per convention, we randomly partitioned our data into 80:20 training:test sets. We fit our regression on the training set >100 values of the regularization parameter lambda and evaluated predictions exclusively on the test set. We repeated this process 100 times to generate CIs for model performance, with our data being randomly partitioned each iteration. Our results were robust to changes in the cross-validation partition, the span of our lambda regularization parameters, and the number of repeat modeling iterations.

**RESULTS**

**Participants**

Demographic information and medical history are provided in Table 1. Of the 516 individuals with COVID–19 who were seen in the ED during the study period, 100 (19%) demonstrated potential evidence of acute cognitive disturbance, but only 68 (13%) met our diagnostic inclusion criteria for delirium. Of the 136 individuals we included in our study, the majority were Caucasian/White (85%), with slightly more females (54%) than males (46%) and an average age of 78 years (range 53–99). There were no between-group differences in age, gender, or ethnicity.

Individuals with delirium were more likely than individuals without delirium to come from assisted living facilities or nursing homes (72%) compared with independent living residences (28%). Individuals with delirium also had higher rates of neurologic comorbidities, particularly dementia and stroke, and psychiatric comorbidities. All dementia subtypes were more common in the delirious group. There were no specific psychiatric comorbidities differences between the two groups, but all five individuals with schizophrenia presented with delirium, which approached significance. Cardiovascular disease was the only medical comorbidity more common in the delirious group.

With respect to other predisposing factors, individuals with delirium were more likely to have a prior history of delirium (49%) than individuals without delirium (13%). Individuals with delirium were also more likely to have at least one deliriogenic medication listed in their medication list and were taking more deliriogenic medications ($M = 1.24, SD = 1.21$) than the individuals without delirium ($M = 0.56, SD = 0.85$): $t_{134} = -3.76$, $P \leq 0.001$. Baseline hearing and visual impairments were more
common in the delirious group but were not significantly different between groups. Presenting signs and symptoms are provided in Table 2. Individuals with delirium were less likely than individuals without delirium to have respiratory symptoms, particularly cough. They were also less likely to report diarrhea or myalgia, but at a marginally significant level. Three individuals presented to the ED

| TABLE 1. Demographic Information and Medical History |
|-----------------------------------------------|--------|--------|--------|--------|--------|--------|
| Demographic/Clinical History                  | M (SD) | With Delirium | Without Delirium | t      | P      |
| Age                                           | 78.25 (10.73) | 78.65 (11.01) | 77.85 (10.63) | -0.428 | 0.669  |
| Gender                                        |        | 37/31       | 37/31       | 0.00   | 1.00   |
| Female/male                                   | 74/62 (54/46) | 37/31       | 37/31       | 0.00   | 1.00   |
| Ethnicity                                     |        |             |             |        |        |
| Caucasian/White                               | 116 (85) | 57         | 59         | 0.06   | 0.81   |
| Asian/Pacific Islander                        | 10 (7)  | 5          | 5          | 0.00   | 1.00   |
| Hispanic/Latinx                               | 5 (4)   | 3          | 2          | 0.00   | 1.00   |
| African American/Black                        | 2 (1)   | 1          | 1          | 0.00   | 1.00   |
| Unknown/unavailable                           | 3 (2)   | 2          | 1          | 0.00   | 1.00   |
| Living situation                              |        |             |             |        |        |
| Assisted/independent                          | 64/72 (47/53) | 19/49       | 45/23       | 18.45  | <0.001***|
| Medical comorbidities                         | 126 (93) | 66         | 60         | 2.7    | 0.1    |
| Hypertension                                  | 92 (68) | 45         | 47         | 0.03   | 0.855  |
| Cardiovascular disease                        | 75 (55) | 44         | 31         | 4.28   | 0.039* |
| Diabetes                                      | 47 (35) | 23         | 24         | 0.00   | 1.00   |
| Chronic lung disease                          | 34 (25) | 16         | 18         | 0.04   | 0.843  |
| Chronic kidney disease                        | 34 (25) | 18         | 16         | 0.04   | 0.843  |
| Obesity                                       | 30 (22) | 15         | 15         | 0.00   | 1.00   |
| Cancer                                        | 29 (21) | 15         | 14         | 0.00   | 1.00   |
| Obstructive sleep apnea                       | 23 (17) | 11         | 12         | 0.00   | 1.00   |
| Liver disease                                 | 11 (8)  | 4          | 7          | 0.40   | 0.529  |
| Neurologic comorbidities                      | 72 (53) | 58         | 14         | 54.57  | <0.001***|
| Dementia                                      | 49 (36) | 44         | 5          | 46.07  | <0.001***|
| Stroke                                        | 25 (18) | 20         | 5          | 9.60   | 0.002**|
| Brain tumor                                   | 5 (4)   | 4          | 1          | 0.83   | 0.366  |
| Parkinson’s disease                           | 4 (3)   | 3          | 1          | 0.26   | 0.619  |
| Seizure disorder                              | 3 (2)   | 3          | 0          | 1.37   | 0.244  |
| Multiple sclerosis                            | 2 (1)   | 2          | 0          | 0.51   | 0.496  |
| Psychiatric comorbidities                     | 74 (54) | 45         | 29         | 6.67   | 0.01*  |
| Depression                                    | 55 (40) | 32         | 23         | 1.95   | 0.162  |
| Anxiety                                       | 30 (22) | 16         | 14         | 0.04   | 0.836  |
| Insomnia                                      | 17 (13) | 12         | 5          | 2.42   | 0.120  |
| Opioid use disorder                           | 12 (9)  | 9          | 3          | 2.29   | 0.131  |
| Alcohol use disorder                          | 8 (6)   | 5          | 3          | 0.13   | 0.718  |
| Bipolar disorder                              | 8 (6)   | 6          | 2          | 1.20   | 0.274  |
| Schizophrenia                                 | 5 (4)   | 5          | 0          | 3.32   | 0.058  |
| Other predisposing factors                    |        |             |             |        |        |
| Prior delirium                                | 42 (31) | 33         | 9          | 17.36  | <0.001***|
| Deliriogenic medications                      | 68 (50) | 44         | 24         | 10.62  | 0.001**|
| Baseline hearing impairment                   | 17 (13) | 11         | 6          | 1.08   | 0.300  |
| Baseline visual impairment                    | 7 (5)   | 5          | 2          | 0.60   | 0.438  |

*Significant at P < 0.05.
**Significant at P < 0.01.
***Significant at P < 0.001.
with ischemic stroke, all of whom had a prior history of stroke. One additional individual experienced a transient ischemic attack 1 week before testing positive for COVID–19, and another experienced a hemorrhagic stroke while hospitalized. One individual presented with nonconvulsive status epilepticus without a prior history of seizure, and one individual displayed suicidal and homicidal behavior. No delirious individuals complained of hypogeusia or hyposmia.

Vital signs, laboratory findings, acute illness-related factors, and hospitalization characteristics are reported in Table 3. Individuals with delirium had higher heart rates and higher sodium compared to individuals without delirium. In the ED, 46% of individuals with delirium had acute respiratory distress syndrome, 34% were dehydrated/malnourished, 31% had hypoxia, 28% had sepsis, 25% had acute kidney injury, and 18% had multiple organ dysfunction. Individuals with delirium were more likely to have hypoxia (oxygen saturation <90%) and sepsis. There were no between-group differences in admission to critical care or use of mechanical ventilation.

Delirium developed within an average of 2 days of initial COVID–19 symptom onset (M = 1.53, SD = 0.97). These individuals were taken to the ED within an average of 4 days of initial symptom onset (M = 3.57, SD = 3.25), which was significantly faster than individuals without delirium (M = 6.7, SD = 4.57): t130 = 4.51, P ≤ 0.001. Symptom onset to death occurred within an average of 11 days in the delirious group (M = 10.74, SD = 9.01, range 1–38) and within an average of 13 days in the nondelirious group (M = 12.84, SD = 6.44, range 3–27): t134 = 0.90, P = 0.374. A total of 57 study participants died, 35 with delirium and 22 without. Mortality included both in-hospital (41) and hospice (16) mortality within 3 months of initial hospitalization date. Individuals with delirium had higher mortality (51%) than individuals without delirium (32%): LR = 1.59, χ²(1) = 4.34, P = 0.037.

In our sample of 68 individuals with delirium due to COVID–19 in the ED, a hypoactive delirium was seen in 62% and a hyperactive delirium was seen in 16%. A mixed level of activity was documented in 22%. Twenty individuals (29%) demonstrated agitation, and five (6%) experienced hallucinations. Delirium without respiratory symptoms was present in 18 individuals (26%), and delirium as the only presenting symptom was seen in six individuals (9%).

All six individuals with delirium as the only presenting symptom of COVID–19 had a prior history of delirium, four had dementia, four had a history of stroke, and two had schizophrenia. These individuals were approximately the same age as the rest of the delirium sample (M = 75.17, SD = 12.13, range 64–91) and had a comparable mortality rate (50%). Only one of these individuals developed respiratory symptoms after admission. Of the three individuals who died, one had a history of brain metastases, dementia, and end-stage renal disease and developed septic shock and multiple organ failure. Symptom onset to death was faster in those with delirium as the only presenting symptom of COVID–19 (M = 3.67, SD = 2.52) compared with those presenting with delirium and other symptoms (M = 11.4, SD = 9.13), but given the limited sample size, this was not statistically significant, t13 = 1.45, P = 0.154.

Our logistic regression contained the following binary predictors (listed with their respective OR and [95% CI representing 2 SDs from the sample M]): use of...
deliriogenic medication (OR: 1.65 [1.10]), history of dementia (OR: 11.02 [1.22]), history of stroke (OR: 4.48 [1.35]), prior delirium (OR: 1.49 [1.24]), and assisted versus independent living (OR 1.65 [1.25]). This model performed on testing sets with 75% sensitivity [9%], 86% specificity [8%], and a total accuracy of 80% [6%]. Each of our parameters had P values <0.05, which is consistent with our univariate analysis.

### Discussion
In our review of 516 consecutive individuals who presented to the ED with COVID–19, 68 individuals (13%) had delirium. The majority of our delirium sample had dementia (65%) and deliriogenic medications in their medication list (65%). Nearly half had a prior history of delirium (49%). All of these factors were significantly more common in the delirious group. The delirious group

---

**TABLE 3. Vital Signs, Laboratory Studies, Acute Illness-related Factors, and Hospitalization Characteristics**

| Vital Signs | M (SD) | With Delirium | Without Delirium | t     | P      | d      |
|-------------|-------|--------------|-----------------|-------|--------|--------|
| Temperature °F | 99.27 (1.58) | 99.39 (1.89) | 99.14 (1.17) | 0.959 | 0.340  | —      |
| Temperature °C | 37.38 (0.88) | 37.45 (1.06) | 37.29 (0.65) | 1.02  | 0.309  | —      |
| Heart rate | 88.35 (22.39) | 93.53 (25.69) | 83.16 (17.18) | 2.76  | 0.007* | 0.47   |
| Respiratory rate | 22.74 (9.02) | 24.12 (11.29) | 21.34 (5.66) | 1.77  | 0.080  | —      |
| Blood pressure systolic | 130.71 (23.78) | 127.12 (25.91) | 134.31 (20.99) | 1.78  | 0.078  | —      |
| Blood pressure diastolic | 71.89 (1.06) | 71.39 (1.95) | 72.38 (10.99) | 0.419 | 0.676  | —      |
| Oxygen saturation | 92.68 (6.73) | 92.06 (8.07) | 93.31 (5.04) | 1.08  | 0.281  | —      |

| Laboratory studies, measurement |
|----------------------------------|
| White blood cell, /µL | 8.42 (5.02) | 8.62 (4.75) | 8.22 (5.29) | 0.459 | 0.647  | —      |
| Hemoglobin, g/DL | 12.16 (2.17) | 11.93 (1.86) | 12.39 (2.43) | 1.25  | 0.212  | —      |
| Hematocrit, % | 37.84 (6.25) | 37.31 (5.21) | 38.43 (7.14) | 0.981 | 0.329  | —      |
| Absolute platelet, 10^3/µL | 214.66 (101.15) | 209.41 (96.81) | 219.91 (105.77) | 0.604 | 0.547  | —      |
| Sodium, mmol/L | 136.79 (6.24) | 138.12 (6.96) | 135.46 (5.14) | 2.53  | 0.012* | 0.43   |
| Potassium, mmol/L | 4.08 (0.61) | 4.09 (0.68) | 4.06 (0.54) | 0.339 | 0.735  | —      |
| Chloride, mEq/L | 96.21 (6.36) | 99.27 (7.13) | 97.15 (5.31) | 1.94  | 0.055  | —      |
| Carbon dioxide, mEq/L | 23.99 (3.79) | 24.22 (4.59) | 23.74 (2.78) | 0.733 | 0.465  | —      |
| Oxygen saturation | 92.68 (6.73) | 92.06 (8.07) | 93.31 (5.04) | 1.08  | 0.281  | —      |

| Acute illness-related factors | n (%) | With Delirium | Without Delirium | χ² | P     |
|------------------------------|-------|--------------|-----------------|-----|-------|
| Acute respiratory distress syndrome | 52 (38) | 31 | 21 | 2.52 | 0.112 |
| Dehydration/malnutrition | 36 (26) | 23 | 13 | 3.06 | 0.080 |
| Hypoxia, < 90% O₂ | 28 (21) | 21 | 7 | 7.60 | 0.006** |
| Acute kidney injury | 26 (19) | 17 | 9 | 2.33 | 0.127 |
| Sepsis | 23 (17) | 19 | 4 | 10.26 | 0.001** |
| Multiple organ dysfunction | 17 (13) | 12 | 5 | 2.42 | 0.120 |
| Congestive heart failure | 7 (5) | 4 | 3 | 0.00 | 1.00 |
| Acute liver failure | 5 (4) | 2 | 3 | 0.00 | 1.00 |

| Hospitalization characteristics | n (%) | With Delirium | Without Delirium | χ² | P     |
|---------------------------------|-------|--------------|-----------------|-----|-------|
| Admission to critical care | 51 (38) | 30 | 21 | 0.231 | 0.631 |
| Mechanical ventilation | 30 (22) | 15 | 15 | 0.00 | 1.00 |
| Mortality | 57 (42) | 35 | 22 | 4.34 | 0.037* |

*Significant at P < 0.05.
**Significant at P < 0.01.
was also more likely to have neurologic (dementia and stroke), psychiatric, and cardiovascular comorbidities as well as higher heart rate, higher sodium, and higher rates of hypoxia and sepsis in the ED. Logistic regression based on five delirium predictors (use of delirigenic medication, history of dementia, history of stroke, prior delirium, and assisted versus independent living) correctly predicted 80% of those with delirium (75% sensitivity at 86% specificity).

The delirious group had higher mortality than the nondelirious group. Just over half of the delirious group died. Delirium developed within an average of 2 days of initial COVID–19 symptom onset, with symptom onset to ED within an average of 4 days, and symptom onset to death within an average of 11 days. Consistent with research on delirium due to COVID–19 and other etiologies, our research suggests that hypoactive delirium is the most common delirium subtype in the older ED patient (Evensen et al, 2018; Han et al, 2009; Kennedy et al, 2020).

Presentations of delirium without respiratory symptoms were seen in 18 individuals (26%), and delirium as the only presenting symptom in six (9%). All six individuals with delirium as the only presenting symptom of COVID–19 in the ED had a prior history of delirium. Three of these individuals died, comparable to the mortality rate of the entire delirium sample, although symptom onset to death occurred within an average of 4 days, implicating a high risk of rapid deterioration in these individuals.

Our results are largely consistent with those of prior studies and suggest that delirium is a common, early occurring, and lethal manifestation of COVID–19 in older adults who present to the ED, in most cases causing acute on chronic neurocognitive dysfunction strongly influenced by inflammatory and hypoxic–ischemic mechanisms. Given the significantly increased risk of mortality in these individuals, a simple risk tool could be used to predict delirium in older adults presenting to the ED with COVID–19, providing an avenue for prevention and treatment to lower mortality.

Although delirium due to COVID–19 has similar risk factors as delirium due to other etiologies, there are several unique characteristics. COVID–19 is a respiratory illness that can present with delirium in the absence of respiratory symptoms, effectively disguising itself as a delirium due to a different etiology. In a subset of older adults with COVID–19 in the ED, delirium was the only presenting symptom. Delirium due to COVID–19 most commonly presents as a hypoactive state in the ED, making it less likely to be detected than hyperactive or mixed delirious states. Thus, regardless of symptomology, clinicians need to remain vigilant of possible COVID–19 in older adults who present to the ED with decreased responsiveness. Finally, there are environmental factors unique to COVID–19 that potentially contribute to increased delirium risk, such as increased anxiety and social isolation resulting from a deadly pandemic, particularly in individuals residing in assisted living and nursing homes where lockdown measures were widespread.

Study Limitations

It is important to consider the present study in context of its limitations. Retrospective chart reviews are associated with underassessment and underdocumentation of delirium symptoms, potentially resulting in an underestimation of true base rates of delirium in similar samples. Our sample size was modest compared to other studies in this area and consisted of medically compromised older adults with high rates of dementia, many of whom were residing in assisted living or nursing homes—the initial epicenters of infection in our area.

Further, our data were gathered from a single hospital in an ethnically homogenous (predominantly White) region of the Northwest United States and included the first reported individuals with COVID–19 in the United States. In this early stage of the pandemic, there was a paucity of information regarding early recognition of COVID–19 and its diverse manifestations in older adults, and no predictive risk tools or available protocols specific for the prevention and management of delirium due to COVID–19 and the unique challenges it presents. These factors limit the generalizability of our findings to younger and healthier individuals, community-dwelling older adults, ethnically diverse individuals and geographic locations, and later stages of the pandemic.

CONCLUSION

Research investigating the long-term sequelae of COVID–19 in hospitalized older adults is quickly accumulating. Given the strong interrelationship between delirium and dementia, both clinically and pathophysiologically, these studies will likely reveal the secondary impact of delirium due to COVID–19: escalating dementia rates. Thus, prevention continues to be the ultimate goal.

Currently, the most effective strategy for reducing delirium due to COVID–19 remains the prevention of infection through vaccination, physical distancing, and mask use. In individuals with COVID–19 not requiring hospitalization, prevention of delirium involves early recognition and medical guidance, as well as reducing modifiable risk factors at home, such as dehydration, malnutrition, alcohol use, polypharmacy, poor sleep, social isolation, sensory deprivation, and reduced activity level. In hospitalized individuals, the prevention of delirium includes empirically supported interventions such as the ABCDEF bundle (Marra et al, 2017) and the Hospital Elder Life Program (Inouye et al, 1999). Difficulties implementing these established protocols during the COVID–19 pandemic have been outlined elsewhere with excellent solutions provided (Kotis et al, 2020; LaHue et al, 2020).

Delirium prevention plans specific to COVID–19 are increasingly being developed, such as those focused on key nursing interventions intended to promote sleep, support adequate nutrition, encourage mobility, maintain or improve cognition, and enhance social support by engaging individuals in meaningful conversations and activities and facilitating virtual visitation with loved ones at least once daily (Radhakrishnan et al, 2021). Continued investigations of the
clinical and pathophysiological characteristics involved in the genesis of delirium due to COVID–19 are also very important to reduce acute risk and severity, thereby mitigating negative long-term outcomes before they occur, and furthering our understanding of delirium more generally.

ACKNOWLEDGMENTS
The authors gratefully thank health care workers across the planet for their courage and humanity during this pandemic.

REFERENCES
2019 American Geriatrics Society Beers Criteria Update Expert Panel. 2019. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. *J Am Geriatr Soc* 67:674–694. doi:10.1111/jgs.15767

Agarwal P, Ray S, Madan A, et al. 2021. Neurological manifestations in 404 COVID–19 patients in Washington State. *J Neurol* 268:770–772. doi:10.1007/s00415-020-10087-z

Ahmed S, Leurent B, Sampson EL. 2014. Risk factors for incident delirium among older people in acute hospital medical units: a systematic review and meta-analysis. *Age Ageing* 43:326–333. doi:10.1093/aging/afu022

Chen T, Wu D, Chen H, et al. 2020. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 368:m1091. doi:10.1136/bmj.m1091

Han JH, Zimmerman EE, Cutler N, et al. 2009. Delirium in older emergency department patients: a quiet epidemic. *Emerg Med Clin North Am* 28:611–631. doi:10.1016/j.emc.2010.03.005

Pranata R, Huang I, Lim MA, et al. 2021. Delirium and mortality in coronavirus disease 2019 (COVID–19): a systematic review and meta-analysis. *Arch Gerontol Geriatr* 95:104388. doi:10.1016/j.archger.2021.104388

Kotfis K, Roberson SW, Wilson JE, et al. 2020. COVID–19: ICU delirium management during SARS-CoV-2 pandemic. *Crit Care* 24:1–9. Published online April 28. doi:10.1186/s13054-020-02882-x

LaHue SC, James TC, Newman JC, et al. 2020. Collaborative delirium prevention in the age of COVID–19. *J Am Geriatr Soc* 68:947–949. doi:10.1111/jgs.16480

Mao L, Jin H, Wang M, et al. 2020. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. *China JAMA Neurol* 77:683–690. doi:10.1001/jamaneurol.2020.1127

Marra A, Ely EW, Pandharipande PP, et al. 2017. The ABCDEF bundle in critical care. *Crit Care Clin* 33:225–243. doi:10.1016/j.ccc.2017.06.006

Poloni TE, Carlos AF, Cairati M, et al. 2020. Prevalence and prognostic value of delirium as the initial presentation of COVID–19 in the elderly with dementia: an Italian retrospective study. *EClinicalMedicine* 26:100490. doi:10.1016/j.eclinm.2020.100490

Radhakrishnan NS, Multi M, Ortiz D, et al. 2021. Implementing delirium prevention in the era of COVID–19. *J Alzheimers Dis* 79:31–36. doi:10.3233/JAD-200696

Tyson B, Erdodi L, Ray S, et al. 2020. Altered mental status in 71 deaths due to COVID–19. *Int J Neurosci* 1-4. Published online October 1. doi:10.1080/00207454.2020.1825422

Tyson B, Erdodi L, Shahein A, et al. 2021. Predictors of survival in older adults hospitalized with COVID–19. *Neural Sci* 42:3953–3958. doi:10.1007/s10072-021-05435-4